Ahmedabad, June 17, June 2017: Zydus Cadila has received the final approval from the USFDA to market Acyclovir for Injection USP in strengths of 500 mg/vial and 1000 mg/vial. Acyclovir for Injection USP which caters to the anti-viral segment, will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad. The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Corporate Comm India(CCI Newswire)
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…